Shingles mRNA vaccine safety and immune response study
Part of Infections clinical trials.
This trial tests a new mRNA vaccine to prevent shingles (herpes zoster). It checks if the vaccine is safe and helps your body build immunity. It's for adults aged 40 or older (phase 1) or 50+ (phase 2).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 40 years or older (phase 1) or 50 years or older (phase 2).
- You never had shingles or chickenpox as an adult, and never got a shingles or chickenpox vaccine before.
- You don't have poorly controlled health conditions like high blood pressure or diabetes.
- You don't have a weak immune system or take medicines that suppress it (like high-dose steroids for more than 14 days).
- You are not pregnant or breastfeeding, and agree to use effective birth control for 6 months after the last dose.
- You have no history of heart muscle inflammation (myocarditis), autoimmune diseases, or bleeding disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new shingles vaccine to see how well it prevents shingles in adults aged 40 and older. It aims to help those who have not had shingles recently or been vaccinated against it before.
This trial tests a new investigational shingles vaccine to see if it is safe and produces an immune response in healthy adults 40 and older. Participating could help protect against shingles and its complications.
This study tests an investigational vaccine (SYS6017) to see how well it works and if it's safe for adults 40 and older. The vaccine aims to prevent shingles, a painful rash caused by the same virus as chickenpox.
This trial tests an experimental vaccine designed to prevent shingles (a painful rash caused by the varicella-zoster virus). It will help see if the vaccine is safe and triggers a good immune response in adults 40 and older.
This trial is testing an experimental mRNA vaccine for preventing shingles. It aims to see if the vaccine is safe and triggers a good immune response in people aged 50 to 79.
This study tests a new vaccine to prevent shingles (a painful rash condition) in adults 50 and older. It checks how safe the vaccine is and how well it triggers the body's immune defense.
Hear when a new Herpes Zoster trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.